Clinical Trial Update: Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CMV-specific cytotoxic T cells in patients with glioblastoma multiforme has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• CMV-Specific Cytotoxic T Cells

Snippet

Sponsor: Baylor College of Medicine | Conditions: Glioblastoma Multiforme, GBM | Phase 1, Phase 2 | Status: TERMINATED